OncoMatch/Clinical Trials/NCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Is NCT04099966 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies alpha beta depletion for acute leukemia.
Treatment: alpha beta depletion — Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Allowed: FLT3 mutation/duplication
FLT3 mutation/duplication
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Exception: unless being done as a boost
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York Medical College · Valhalla, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04099966 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 30 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify